
Associate Scientist, Post Doc Fellow- Computational Pathology & Spatial AI
Merck
Summary
Within DAGS, our AI/ML team develops biologically grounded and interpretable machine learning methods to accelerate biomarker discovery across oncology. We are seeking a highly motivated Postdoctoral Research Fellow to develop next-generation multimodal AI approaches that integrate histopathology, transcriptomics, and spatial biology to characterize tumor microenvironment architecture and generate novel biological insights from routine H&E pathology images.
Job description
What You'll Do
- Advance AI/ML methods that connect pathology images with molecular and spatial biology data.
- Develop interpretable computational approaches to study tissue organization, tumor microenvironment biology, and disease-relevant patterns.
- Integrate multimodal datasets to support biomarker discovery and biological hypothesis generation.
- Collaborate with multidisciplinary teams across data science, pathology, biology, and translational research.
- Communicate scientific findings through presentations, publications, and cross-functional discussions.
Education Requirement
Must currently hold a PhD OR receive a Ph.D. no later than spring 2027 in Computer Science, AI/ML, Computational Biology, Bioinformatics, Biomedical Engineering, Statistics, Applied Mathematics, or a related quantitative discipline.
Required Skills and Experience
- Computational Pathology, Deep Learning, Computer Vision, Multimodal AI, Transcriptomics, Foundation Models, Oncology, Tumor Microenvironment, Spatial Biology.
- Strong expertise in machine learning, deep learning, and data science.
- Proficiency in Python and deep learning frameworks such as PyTorch.
- Experience with computer vision, representation learning, multimodal modeling, or biomedical data analysis.
- Demonstrated research productivity through publications, preprints, or conference presentations.
- Ability to communicate complex technical concepts to multidisciplinary scientific teams.
Preferred Skills and Experience
- Computational pathology.
- Spatial transcriptomics, RNA-seq, or single-cell omics analysis.
- Foundation models, transformers, and multimodal learning.
- Tumor microenvironment biology and oncology biomarker discovery.
- Publications in venues such as MICCAI, CVPR, NeurIPS, ISMB, AACR, or related journals.
Requirements
- Must currently hold a PhD or receive a PhD no later than spring 2027
- PhD in Computer Science, AI/ML, Computational Biology, Bioinformatics, Biomedical Engineering, Statistics, Applied Mathematics, or a related quantitative discipline
- Strong expertise in machine learning, deep learning, and data science
- Proficiency in Python and deep learning frameworks such as PyTorch
- Experience with computer vision, representation learning, multimodal modeling, or biomedical data analysis
- Demonstrated research productivity through publications, preprints, or conference presentations
- Ability to communicate complex technical concepts to multidisciplinary scientific teams
Benefits
- Medical, Dental & Vision
- 401(k) Matching
- Paid Holidays
- Vacation
- Sick Days
- Annual Bonus
- Long-Term Incentive
Company overview
Merck & Co., Inc., known as Merck in the United States and Canada and MSD (Merck Sharp & Dohme) internationally, is a premier American multinational pharmaceutical company headquartered in Rahway, New Jersey. Founded in 1891 as the U.S. subsidiary of the German Merck Group, the company became independent following World War I and has since grown into one of the world's largest biomedical companies, ranking fourth globally by revenue. Merck operates across three core business segments: pharmaceuticals, vaccines, and animal health products. The company is renowned for its groundbreaking research and development, having brought numerous life-saving medicines to market including Keytruda (pembrolizumab), a leading immunotherapy for cancer treatment that generated $29.5 billion in 2024 revenue, and Gardasil, a revolutionary HPV vaccine. With approximately 75,000 employees worldwide, Merck maintains a robust pipeline of innovative therapies focused on oncology, vaccines, hospital acute care, cardiology, neuroscience, virology, immunology, and diabetes. The company invests heavily in R&D, spending $17.9 billion in 2024 alone, demonstrating its commitment to advancing scientific discovery. Merck's legacy spans over 130 years of bringing hope to humanity through important medicines and vaccines, operating with a purpose to use leading-edge science to save and improve lives globally while fostering an inclusive workforce and responsible business practices.